DEA scheduling vs FDA approval: what's the difference for peptides

Background

Two federal frameworks govern access to a drug in the United States, and they are administered by two different agencies. The Food and Drug Administration (FDA) decides whether a drug may be marketed for an indication, on the basis of substantial evidence of effectiveness and safety (FDA Drug Approval Process). The Drug Enforcement Administration (DEA) decides whether a drug is a “controlled substance” — that is, whether its manufacture, prescription, and possession are restricted by the Controlled Substances Act (CSA) — and, if so, into which of five schedules it falls (StatPearls — DEA Drug Scheduling).

These two questions — “is the drug approved?” and “is the drug scheduled?” — are independent. A drug can be FDA-approved and unscheduled (most antibiotics), FDA-approved and scheduled (oxycodone, ketamine), unapproved and scheduled (most plant-derived hallucinogens), or unapproved and unscheduled (most investigational peptides).

What FDA approval is

FDA approval is a marketing authorization. The agency’s review staff evaluates a sponsor’s new drug application or biologics license application against statutory criteria for safety and effectiveness for a specific indication, dosage form, route of administration, and patient population. The agency may approve the application in full, approve with restrictions (e.g., a Risk Evaluation and Mitigation Strategy), or issue a complete response letter declining approval. FDA approval applies only to the labeled indication and to the specific manufactured product reviewed.

A separate but related FDA pathway — the Pharmacy Compounding Advisory Committee process under section 503A — applies to bulk drug substances used in compounded preparations rather than to a finished commercial product. PCAC is the venue currently considering peptides such as BPC-157, TB-500, and MOTs-C (STAT News, April 15, 2026). Compounding is governed by FDA, not by DEA.

What DEA scheduling is

DEA scheduling is a controlled-substance designation. Under the CSA, a substance is placed in Schedule I (no accepted medical use, high abuse potential), Schedule II, III, IV, or V (accepted medical use, decreasing abuse potential), or remains uncontrolled. Scheduling decisions are administered by DEA, but DEA is required to obtain a scientific and medical evaluation and scheduling recommendation from the Department of Health and Human Services before initiating rulemaking. HHS has delegated that scientific evaluation to FDA’s Controlled Substance Staff within the Center for Drug Evaluation and Research (FDA Controlled Substance Staff page).

The interagency mechanism is described in MOU 225-15-11 between FDA and DEA, which outlines information sharing, evaluation responsibilities, and coordination on Schedule I research protocols (FDA-DEA MOU 225-15-11). FDA’s input is binding on DEA on the scientific and medical questions; DEA retains discretion on the legal question of scheduling.

Why most peptides are not DEA-scheduled

The CSA was written primarily with small-molecule drugs of abuse in mind — opioids, stimulants, hallucinogens, sedatives. Peptides as a class are not categorically excluded from scheduling, but in practice DEA has very rarely scheduled a peptide. The scheduling criteria — actual or relative potential for abuse, scientific evidence of pharmacological effect, history and current pattern of abuse, scope and significance of the abuse, risk to the public health, dependence liability, and whether the substance is an immediate precursor of an already controlled substance — are difficult to satisfy for a substance that is destroyed by gastric acid, has limited oral bioavailability, and has no documented pattern of recreational misuse.

The peptides being reviewed by PCAC on July 23-24, 2026 — BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon — are not DEA-controlled substances. None appears on the DEA’s controlled substances schedule. A negative PCAC outcome on those peptides would affect only their compounding status under FDA, not their CSA classification.

Common points of confusion

A few practical clarifications often arise in coverage of peptide regulation:

• “Banned by the FDA” is informal shorthand. It usually refers to placement in Category 2 of FDA’s interim 503A policy, which restricts compounding. It does not impose criminal penalties on possession.
• “Schedule III steroid” rules do not apply to most peptides. Anabolic-androgenic steroids are Schedule III by statute. Peptide hormones like growth-hormone-releasing peptides occupy a distinct regulatory space and are typically unscheduled at the federal level, although individual states may impose additional restrictions.
• WADA prohibition is not DEA scheduling. The World Anti-Doping Agency maintains its own list for elite sport. WADA inclusion has no domestic legal effect in the United States.

Practical takeaway

For a peptide such as BPC-157, TB-500, or MOTs-C, the regulatory questions are: (1) does FDA permit it to be compounded by 503A pharmacies (currently no — these peptides are in Category 2 pending PCAC review), and (2) does FDA permit a sponsor to market it as an approved drug (no — none has an approved NDA or BLA). The DEA question — controlled-substance scheduling — does not currently apply.